FDA to issue guidance on therapy for opioid addiction: 5 insights

Megan Wood -   Print  |

The FDA will introduce guidance on more access to medication-assisted treatment for opioid addiction, CNN reports.

Here are five insights.


1. HHS Secretary Alex Azar commented on the coming guidance at a National Governor's Association's meeting Feb. 24.


2. Medication-assisted treatment includes behavioral therapy and medications to help cut cravings and withdrawal symptoms. Medications often used are buphrenorphine and methadone. The FDA approved methadone, naltrexone and buprenorphine for opioid addiction treatment.


3. During the meeting, CNN reported Mr. Azar said, "Medication-assisted treatment works. The evidence on this is voluminous and ever-growing."


4. The FDA guidance will emphasize the need for developing new forms of the opioid-addiction fighting drugs, such as an injectable formulation of buprenorphine.


5. The FDA will also comment on studies investigating the efficacy of medication-assisted treatment.


More articles on practice management:
Rothman Institute partners with Franklin Bioscience to research medical marijuana: 4 insights
Crystal Clinic announces $100M orthopedic hospital plans: 5 things to know
Evergreen Health develops integrated facility of spine, orthopedic & neurosurgeons: 4 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers